Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPS Block for Post-VATS Analgesia
NCT05972122Withdrawn
- Sponsor
- Istanbul Medipol University
- Start
- Aug 2023
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, single-blind trial of bupivacaine hydrochloride 0.75% injection in postoperative pain (2 arms), sponsored by Istanbul Medipol University. Primary endpoint: Opioid consumption (Fentanyl PCA) at 24 hours. Planned start Aug 2023; status: withdrawn.
02
Drugs
bupivacaine hydrochloride 0.75% injection
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT05972122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05972122.